highly significantp < 0.001
Bleeding Data from 7 trials ( n = 27,743) showed 527/13,865 bleeding events (3.80%) with potent P2Y12 monotherapy versus 840/13,878 (6.05%) with DAPT, a highly significant difference (HR 0.55, 95% CI [0.42–0.71]; p < 0.001; I2 = 79.0%) ( Fig 2A ).